Abstract: An object of the present invention is to provide a compound for modulating expression of Major Histocompatibility Complex Class I (MHC-1) and/or TAP-1, in eukaryotic cells. In certain aspects, the compound is a curcuphenol, a terpene or a cannabinoid. Also provided are a composition that comprises the compound and methods of use thereof, for instance, for augmenting an immune response involving MHC-1 CTL, treating cancer, or treating a disease associated with histone acetylation abnormalities.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: Therapeutic agents targeted to voltage gated calcium channels and compositions comprising such therapeutic agents are provided, as is the use of such agents and compositions to modulate the function of haematopoietic cells expressing the voltage gated calcium channel. Also provided are methods of screening for agents that target a given voltage gated calcium channel that are suitable for use as therapeutics to modulate the activity of cells expressing the targeted voltage gated calcium channel. The agent can be, for example, an antibody, an aptamer, a peptide or a small molecule capable of binding to an ectodomain of the target voltage gated calcium channel and thus of modulating the function of the calcium channel.